<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12216858</article-id><article-id pub-id-type="pmcid-ver">PMC12216858.1</article-id><article-id pub-id-type="pmcaid">12216858</article-id><article-id pub-id-type="pmcaiid">12216858</article-id><article-id pub-id-type="pmid">40596600</article-id><article-id pub-id-type="doi">10.1038/s41598-025-07401-y</article-id><article-id pub-id-type="publisher-id">7401</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Sensitive RP-HPLC method with fluorimetric detection for concurrent quantification of emtricitabine, Daclatasvir and Ledipasvir in human urine</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Youssef</surname><given-names initials="AA">Aya A.</given-names></name><address><email>aya.youssef@pharma.asu.edu.eg</email><email>aya.atef11@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Magdy</surname><given-names initials="N">N.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hussein</surname><given-names initials="LA">Lobna A.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>El-Kosasy</surname><given-names initials="AM">A. M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cb9w016</institution-id><institution-id institution-id-type="GRID">grid.7269.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0621 1570</institution-id><institution>Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, </institution><institution>Ain Shams University, </institution></institution-wrap>Organization of African Unity Street, Abassia, Cairo, 11566 Egypt </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>22393</elocation-id><history><date date-type="received"><day>7</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-03 10:25:18.720"><day>03</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_7401.pdf"/><abstract id="Abs1"><p id="Par1">Co-infection with hepatitis C virus (HCV) in human immunodeficiency virus (HIV) patients is common and has a poor prognosis leading to many complications. The anti-HIV drug emtricitabine (FTC) is co-administered with two direct acting anti-HCV drugs; daclatasvir (DAC) and ledipasvir (LDV). The three drugs are simultaneously determined in human urine for the first time by a validated, simple and sensitive RP-HPLC with programmed fluorescence detection. The column used is Exsil 100 ODS C18 column (250&#8201;&#215;&#8201;4.6&#160;mm, 5&#160;&#956;m). The used mobile phase is acetonitrile: methanol: 0.01&#160;M ammonium acetate buffer, pH 4.5 in ratio (20: 60: 20) in isocratic mode pumped at flow rate 1 mL/min. The proposed method is successfully validated according to FDA bioanalytical validation guidelines. The calibration curves are linear over the ranges (500-15000, 1&#8211;50 and 10&#8211;100 ng/mL) with average recoveries (97.9-99.54%, 98.78-104.17% and 98.49&#8211;100.96%) for FTC, DAC and LDV, respectively. The intraday and inter-day accuracy and precision results are within the acceptable limits. Stability assays reveal that the three studied drugs were stable during preparation, injection and storage. The method can be applied for the quantification of the three drugs co-administered to HIV/HCV co-infected patients&#8217; urine which aids in therapeutic drug monitoring and dosage adjustment for chronic patients.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Emtricitabine</kwd><kwd>Daclatasvir</kwd><kwd>Ledipasvir</kwd><kwd>Bioanalytical validation</kwd><kwd>HIV/HCV co-infection</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Analytical chemistry</kwd><kwd>Medicinal chemistry</kwd><kwd>Infectious diseases</kwd><kwd>Public health</kwd></kwd-group><funding-group><award-group><funding-source><institution>Ain Shams University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Acquired immunodeficiency syndrome (AIDS) is still regarded as a challenging global public health issue. It is caused by human immunodeficiency virus (HIV) infection. HIV infections often develop multiple complications and comorbidities. At the end of year 2021, the Joint United Nations Program on HIV/AIDS (UNAIDS) reported that the prevalence of HIV among adults was 0.7% with 650,000 AIDS-related deaths around the world<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Infection with hepatitis C virus (HCV) is the most common co-infection in HIV patients since both infections share similar routes of transmission<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Additionally chronic HCV infection is a major public health problem affecting 1% of the world population<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. HCV causes chronic liver disease and cirrhosis which if untreated results in hepatocellular carcinoma leading to significant mortality. Thus, patients co-infected with HCV and HIV are susceptible to significant complications and rapid disease progression compared to HCV mono-infected patients. As a result, treatment of HCV/HIV co-infection is complicated and requires early intervention with long-term combined treatment protocols<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par3">HIV/HCV combined treatment protocols include antiretroviral therapy (ART) for HIV treatment and direct-acting antivirals (DAAs) against HCV<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. In the last decade DAAs class replaced the old standard HCV treatment and proved better antiviral efficacy. Recently, the common HCV treatment protocols include one or more drugs from the DAAs such as sofosbuvir, ledipasvir and daclatasvir<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. While the most common ART used against HIV are emtricitabine and tenofovir<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. According to the patient&#8217;s condition certain combination drug regimens are applied for instance, emtricitabine used for long term therapy for HIV can be co-administered with DAC and LDV<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. Therefore, HIV/HCV co-infected patients follow prolonged treatment protocols which necessitates close monitoring and follow-up to detect the drugs levels in biological fluids.</p><p id="Par4">Emtricitabine (FTC) is used in the treatment of HIV in combination with other antiretroviral therapy (ART), its chemical structure is depicted in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. FTC is nucleoside reverse transcriptase inhibitor (NRTI), it inhibits reverse transcriptase&#8211;catalyzed mRNA-dependent DNA and thus ends the amino acid chain of generated viral DNA<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. FTC is also a key component of pre-exposure prophylaxis (PrEP) for HIV prevention used for HIV-negative persons at risk of infection<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. A number of published HPLC methods have been applied for the analysis of FTC in combination with other drugs in dosage form<sup><xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref></sup>. All the mentioned HPLC methods used UV or PDA detection. But only one method has been reported for FTC determination by RP-HPLC using fluorescence detector in plasma<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Noticeably, the literature is devoid of any HPLC method measuring FTC in human urine although pharmacokinetic data report that FTC is detectable in urine unchanged<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.</p><p id="Par5">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Chemical structures of emtricitabine, daclatasvir and ledipasvir.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e265" position="float" orientation="portrait" xlink:href="41598_2025_7401_Fig1_HTML.jpg"/></fig>
</p><p id="Par6">Both daclatasvir (DAC) and ledipasvir (LDV) belong to the direct-acting antivirals (DAAs) class used for HCV infection treatment (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>)<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. DAC and LDV are selective inhibitors of HCV non-structural 5&#160;A (NS5A) protein. NS5A protein is vital for HCV replication and cellular signaling pathways regulation. They are commonly used in HCV treatment regimens and co- administered with other drugs such as sofosbuvir and/or ribavirin<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>.Few HPLC-DAD methods have been published for determination of DAC or LDV in dosage forms<sup><xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref></sup>. Whereas, DAC and LDV were determined simultaneously with other DAAs or ribavirin either in bulk or in dosage forms by a number of HPLC methods with UV detection<sup><xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref></sup>. A review of the published analytical methods indicates that no HPLC methods employing fluorescence detection have been reported for the simultaneous determination of FTC, DAC and LDV in urine. Only a single method has been documented for the determination of DAC alone, and that was limited to pharmaceutical dosage form<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>.</p><p id="Par7">In addition, the three studied analytes exhibit native fluorescence, rendering them suitable for fluorescence detection<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. Fluorescence detection offers some advantages over UV detection: it provides high sensitivity, allowing detection limits in the nano-range, and high selectivity, with minimal interference from non-fluorescent components. Hence, fluorescence detection is well-suited for the determination of drugs in biological matrices, owing to its high sensitivity and selectivity at specific excitation and emission wavelengths, which significantly minimizes matrix effects. Accordingly, analyte quantification using a fluorescence detector is considered beneficial due to its sensitivity and selectivity.</p><p id="Par8">It was reported that FTC is primarily eliminated by kidneys and excreted predominantly in urine; 86% of the administered dose is excreted in urine<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. While DAC and LDV are excreted unchanged in patients&#8217; urine as percentages 6.6% and 1% respectively<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>. Biological analysis of drugs in urine specimens is simpler relative to other biological fluids. Urine collection is non-invasive, particularly suitable for all age groups and requires minimal preparations prior to analysis<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. Despite the presence of FTC, DAC and LDV in detectable concentrations in patients&#8217; urine and the ease of using urine specimens in drugs analysis, till now there is no published HPLC method in literature for determination of the three analyzed drugs simultaneously in human urine. Hence, this study shows the first, sensitive and simple HPLC method with fluorescence detection for the determination of FTC, DAC and LDV in human urine reaching ultrasensitive concentrations.</p><p id="Par9">It is worth mentioning that, applying an HPLC method is simpler, cost effective with lower maintenance and operational expenses in contrast to LC-MS/MS that is not accessible in some labs especially in developing countries. Also, HPLC is well-established in clinical settings for routine therapeutic drug monitoring (TDM) and provides reliable sensitivity and selectivity for many analytes. Considering the clinical role of TDM for optimizing antiviral therapy, particularly in special populations such as co-infected patients with HIV/HCV aiming to better clinical outcomes. The developed sensitive and selective HPLC method for the simultaneous determination of FTC, DAC, and LDV in urine using fluorescence detection is highly warranted for treatment optimization.</p></sec><sec id="Sec2"><title>Experimental</title><sec id="Sec3"><title>Chemicals and reagents</title><p id="Par10">Emtricitabine (99.6% purity) was purchased from Sigma-Aldrich (USA). Daclatasvir (99.8% purity) and ledipasvir (99.6% purity) were obtained from ALSACHIM (France). All utilized solvents were HPLC gradient grade (99.9% purity). Water, methanol and acetonitrile were bought from Sigma-Aldrich (USA). Ammonium acetate and chloroform were purchased from FischerScientific (Cornell Lab, Cairo, Egypt). Urine samples were collected from healthy male adult (age 30&#8211;44) human volunteers.</p></sec><sec id="Sec4"><title>Instrumentation</title><p id="Par11">The chromatographic separation and analysis of the studied analytes was conducted using VWR<sup>&#174;</sup> Hitachi Chromaster HPLC-DAD-FL system equipped with autoinjector, quaternary pump, vacuum degasser, Hitachi Chromaster 5430 diode array detector and Hitachi Chromaster 5440 fluorescence detector (Japan). The used stationary phase was reversed phase Dr. Maisch GmbH (Ammerbuch, Germany) Exsil 100 ODS C18 column (250&#8201;&#215;&#8201;4.6&#160;mm, 5&#160;&#956;m). Jenway digital pH meter was used to adjust and determine pH of buffer solution. VELP Scientifica RX3 vortex mixer, BOECO centrifuge SC-8 and Eppendorf<sup>&#174;</sup> concentrator 5301 were used for sample preparation.</p></sec><sec id="Sec5"><title>Chromatographic conditions</title><p id="Par12">The used mobile phase was acetonitrile: methanol: 0.01&#160;M ammonium acetate buffer, pH 4.5 in ratio (20: 60: 20) pumped at flow rate 1 mL/min. The column was set at room temperature (25 &#186;C) during the chromatographic separation. The programmed fluorescence detector (FLD) was set at different excitation (&#955;<sub>exc</sub>) and emission (&#955;<sub>em</sub>) wavelengths specific to each determined drug throughout the 15&#160;min of the run time as illustrated in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The injected volume by the autoinjector was 20 &#181;L. Pre-washing of the column was done daily for 30&#8211;45&#160;min prior to sample injection by water and methanol in different ratios, or as needed, to remove retained carryover if any and to extend column lifetime. Conditioning for 10&#160;min with the mobile phase was done between runs before each analysis to ensure column equilibration and stable baseline.</p><p id="Par14">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Programmed FLD setup showing &#955;<sub>exc</sub>, &#955;<sub>em</sub> of the studied drugs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Time interval (min)</th><th align="left" colspan="1" rowspan="1">Excitation wavelength (&#955;<sub>exc</sub>) (nm)</th><th align="left" colspan="1" rowspan="1">Emission wavelength (&#955;<sub>em</sub>) (nm)</th><th align="left" colspan="1" rowspan="1">Separated drug</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">0&#8211;4</td><td char="." align="char" colspan="1" rowspan="1">270</td><td char="." align="char" colspan="1" rowspan="1">350</td><td align="left" colspan="1" rowspan="1">Emtricitabine</td></tr><tr><td align="left" colspan="1" rowspan="1">4&#8211;7</td><td char="." align="char" colspan="1" rowspan="1">300</td><td char="." align="char" colspan="1" rowspan="1">380</td><td align="left" colspan="1" rowspan="1">Daclatasvir</td></tr><tr><td align="left" colspan="1" rowspan="1">7&#8211;15</td><td char="." align="char" colspan="1" rowspan="1">340</td><td char="." align="char" colspan="1" rowspan="1">420</td><td align="left" colspan="1" rowspan="1">Ledipasvir</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec6"><title>Preparation of calibration standards and quality control samples</title><p id="Par15">Stock solutions (500&#160;&#181;g/mL) of FTC, DAC and LDV were prepared in methanol and stored at 4 &#186;C. On the day of analysis, working solutions of each analyte were prepared with the following concentrations 250, 10 and 100&#160;&#181;g/mL for FTC, DAC and LDV respectively. A mixture of the analytes with lower concentrations were prepared in nine 10 mL volumetric flasks (6 calibrators and 3 QC samples) by accurately transferring appropriate volumes from each working solution. The prepared concentrations of the mixture denoted as C<sub>mix</sub> are stated in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. From each volumetric flask 100 &#181;L were accurately transferred to 900 &#181;L urine for spiking to reach final volume 1000 &#181;L spiked urine with final concentrations denoted C<sub>f</sub>. Urine samples for spiking were collected after the approval of the Research Ethics Committee at Faculty of Pharmacy, Ain Shams University, Cairo, Egypt, with approval number: REC#285. All the procedures were done in accordance to the committee&#8217;s guidelines and after obtaining informed consents from all addressed subjects.</p><p id="Par17">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Preparation of calibrators and quality control samples for FTC, DAC and LDV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Prepared samples</th><th align="left" rowspan="2" colspan="1">Volume of urine</th><th align="left" colspan="3" rowspan="1">Concentration of each analyte in the prepared mixture before spiking (C<sub>mix</sub>) (ng/mL)</th><th align="left" rowspan="2" colspan="1">Final volume after spiking</th><th align="left" colspan="3" rowspan="1">Final concentration of each analyte in urine (C<sub>f</sub>) (ng/mL)</th></tr><tr><th align="left" colspan="1" rowspan="1">FTC</th><th align="left" colspan="1" rowspan="1">DAC</th><th align="left" colspan="1" rowspan="1">LDV</th><th align="left" colspan="1" rowspan="1">FTC</th><th align="left" colspan="1" rowspan="1">DAC</th><th align="left" colspan="1" rowspan="1">LDV</th></tr></thead><tbody><tr><td align="left" rowspan="6" colspan="1">Calibrators</td><td align="left" rowspan="9" colspan="1">900 &#181;L</td><td align="left" colspan="1" rowspan="1">5,000</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" rowspan="9" colspan="1">1000 &#181;L</td><td align="left" colspan="1" rowspan="1">500</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td></tr><tr><td align="left" colspan="1" rowspan="1">20,000</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">200</td><td align="left" colspan="1" rowspan="1">2000</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">20</td></tr><tr><td align="left" colspan="1" rowspan="1">50,000</td><td align="left" colspan="1" rowspan="1">200</td><td align="left" colspan="1" rowspan="1">400</td><td align="left" colspan="1" rowspan="1">5000</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">40</td></tr><tr><td align="left" colspan="1" rowspan="1">90,000</td><td align="left" colspan="1" rowspan="1">300</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1">9000</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">60</td></tr><tr><td align="left" colspan="1" rowspan="1">120,000</td><td align="left" colspan="1" rowspan="1">400</td><td align="left" colspan="1" rowspan="1">800</td><td align="left" colspan="1" rowspan="1">12,000</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">80</td></tr><tr><td align="left" colspan="1" rowspan="1">150,000</td><td align="left" colspan="1" rowspan="1">500</td><td align="left" colspan="1" rowspan="1">1000</td><td align="left" colspan="1" rowspan="1">15,000</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">100</td></tr><tr><td align="left" colspan="1" rowspan="1">QCL</td><td align="left" colspan="1" rowspan="1">15,000</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">300</td><td align="left" colspan="1" rowspan="1">1500</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">30</td></tr><tr><td align="left" colspan="1" rowspan="1">QCM</td><td align="left" colspan="1" rowspan="1">70,000</td><td align="left" colspan="1" rowspan="1">250</td><td align="left" colspan="1" rowspan="1">500</td><td align="left" colspan="1" rowspan="1">7000</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">50</td></tr><tr><td align="left" colspan="1" rowspan="1">QCH</td><td align="left" colspan="1" rowspan="1">130,000</td><td align="left" colspan="1" rowspan="1">450</td><td align="left" colspan="1" rowspan="1">900</td><td align="left" colspan="1" rowspan="1">13,000</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">90</td></tr></tbody></table><table-wrap-foot><p>C<sub>mix</sub>: Concentration of the drug in the mixture, C<sub>f</sub>: Final drug concentration in spiked urine, QCL: Quality Control sample Low, QCM: Quality Control sample Middle, QCH: Quality Control sample High.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec7"><title>Urine sample extraction and preparation</title><p id="Par23">FTC, DAC and LDV were extracted from spiked urine samples by liquid-liquid extraction. Three mL chloroform were added to 1 mL spiked urine and vortexed by RX3 VELP vortex mixer for 10&#160;s. Then centrifugation at 2,800 RCF using BOECO centrifuge SC-8, for 15&#160;min to separate the immiscible organic layer from the spiked urine aqueous layer. The denser organic chloroform layer was carefully transferred into clean Eppendorf<sup>&#174;</sup> microcentrifuge tube to be evaporated for 20&#160;min till dryness using Eppendorf<sup>&#174;</sup> concentrator 5301 under vacuum at 25&#160;&#176;C. The residue was reconstituted in 1 mL of the mobile phase, vortexed for 10&#160;s and filtered through 0.45&#160;&#956;m filter. After filtration, 20 &#181;L were injected into the HPLC system.</p></sec><sec id="Sec8"><title>Method validation</title><p id="Par24">The method was validated in accordance with the US Food and Drug Administration guidance for bioanalytical method validation<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>.</p><sec id="Sec9"><title>Selectivity</title><p id="Par25">Six different blank samples of human urine from different volunteers (males, age 30&#8211;44) were prepared and analyzed. By comparing the chromatograms of the blank and that of the spiked analytes urine samples at LLOQ levels, any interference by the matrix can be assessed. The blank urine samples should be free of interference at the retention times of the analytes which means that, blank should be &lt;&#8201;20% of the analyte response at the LLOQ.</p></sec><sec id="Sec10"><title>Linearity</title><p id="Par26">Spiked urine samples were prepared in the ranges of (500-15000 ng/mL, 1&#8211;50 ng/mL and 10&#8211;100 ng/mL) for FTC, DAC and LDV respectively as depicted in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. They were injected under the mentioned HPLC conditions and areas of the resulting peaks analytes were calculated. The peak areas were plotted against their corresponding concentrations and the regression equations were calculated.</p></sec><sec id="Sec11"><title>Accuracy and precision</title><p id="Par27">Accuracy and precision of the assay were determined by analysis of the QC samples at four concentration levels (LLOQ, QCL, QCM and QCH). The intra-day (within-run) and inter-day (between-run) accuracy and precision were assessed by analysis of five replicates of QC samples within the same day and on three consecutive days. Precision was expressed as a percentage of relative standard deviation (%RSD).</p></sec><sec id="Sec12"><title>Recovery</title><p id="Par28">The recoveries of FTC, DAC and LDV from urine for three levels QC samples (QCL, QCM and QCH) were determined. They were calculated by comparing the peak areas of the human urine samples spiked by the analytes then extracted to that of the post extracted human urine samples spiked by the analytes at the same concentrations. Thus, the recoveries and the extraction efficiency of the method can be evaluated.</p></sec><sec id="Sec13"><title>Stability</title><p id="Par29">The stability of the analytes determined in human urine was evaluated by analyzing three replicates of QCL and QCH samples. By comparing peak areas of newly prepared spiked urine samples to that exposed to different conditions of storage and temperature. For freeze and thaw stability, samples were subjected to three freeze and thaw cycles for 72&#160;h. Whereas, for benchtop stability the samples were left for approximately 8&#160;h at ambient temperature. Ultimately, for processed sample stability the samples were kept in the autosampler for 24&#160;h at ambient temperature to access if possible degradation of the sample might take place due to delay in injection.</p></sec><sec id="Sec14"><title>Robustness</title><p id="Par30">Robustness was evaluated by analyzing FTC, DAC and LDV after slight but intentional changes in the separation conditions. Flow rate was changed by (&#177;&#8201;0.1&#160;ml/min), buffer pH was changed by (&#177;&#8201;0.2 units) also; organic strength in the mobile phase composition was varied by (&#177;&#8201;2%) in methanol. The % relative standard deviation (%RSD) was calculated for the obtained recoveries of the analytes QCM before and after these changes.</p></sec></sec></sec><sec id="Sec15"><title>Results and discussion</title><p id="Par31">This work aims to develop a new HPLC method to determine three co-administered drugs for the treatment of HIV/HCV co-infection. Determination of these drugs is challenging to evaluate patients&#8217; conditions and drug adherence that ultimately impacts public health. To our information, this is the first reported HPLC method for simultaneous determination of FTC, DAC and LDV in human urine. Moreover, using fluorimetric detector renders the method sensitive to detect the mentioned drugs even in the nano-range concentrations. Additionally, all determinations were carried out in human urine which can be obtained easily by noninvasive procedures unlike other matrices. Consequently, the method is proposed to be applied in therapeutic drug monitoring for chronic HIV/HCV patients owing to its low cost, sensitivity and simplicity.</p><sec id="Sec16"><title>Method development</title><sec id="Sec17"><title>Optimization of chromatographic conditions</title><p id="Par32">A successful analysis of ternary mixture of FTC, DAC and LDV was developed using isocratic HPLC method with fluorimetric detection. The method conditions were optimized to achieve acceptable resolution, peak shape, sensitivity and short analysis time. Various trials were carried out to optimize the mobile phase composition aiming to achieve the best separation. Basically, water and acidic water were tried but weren&#8217;t suitable for separating FTC. Buffers such as phosphate and acetate were tested at different pH ranges (pH 4.0 to 8.5). Ammonium acetate buffer at pH 4.5 was selected based on the ionization states of studied analytes to achieve optimal resolution, symmetric peaks without tailing and appropriate retention times. The concentration of the buffer was optimized by trying concentrations range from 0.01 to 0.05&#160;M and 0.01&#160;M was the selected one. Generally, low-concentration buffers are preferred in HPLC to minimize detector interference, prevent salt precipitation and extend column lifetime.</p><p id="Par33">Organic modifiers (methanol, acetonitrile or ethanol) were tried at various ratios with ammonium acetate buffer. Each of methanol and acetonitrile at 80% could separate the three analytes however, the resulted peaks in case of methanol were broad and in case of acetonitrile were eluted earlier and overlapped with early urine co-eluting peak but they are narrower compared to that of methanol alone. Thus, a mixture of both methanol, acetonitrile together with 0.01&#160;M ammonium acetate buffer in ratio 60:20:20 was selected to achieve sharper, well-resolved peaks without interference.</p><p id="Par34">The column temperature was kept at ambient temperature (approx. 25 &#186;C) throughout the separation. This is consistent with the majority of previously reported HPLC methods analyzing each of FTC, DAC and LDV all of which operated at ambient temperature, except one method for FTC determination increased the column temperature to 35 &#186;C<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. This elevated temperature was tried in the present study however, it didn&#8217;t affect the separation significantly. Therefore, the column temperature was maintained at ambient temperature.</p></sec><sec id="Sec18"><title>Sample extraction optimization</title><p id="Par35">Urine samples are commonly used in drug testing due to their ease of collection and the relatively simple procedures required for analysis which is considered a noninvasive, low-cost testing alternative. In many cases, urine samples are diluted with water or a mixture of water and buffer, filtered then directly injected to HPLC column. This simplicity makes urine an attractive matrix for detecting drugs, as it minimizes the time and resources needed for sample preparation while still providing reliable results. However, some reports highlight that to achieve a more purified form of the drugs, urine samples may undergo extraction methods. Techniques such as protein precipitation or liquid-liquid extraction using specific organic solvents are employed to isolate the drugs from the urine matrix more effectively<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. These methods help to enhance the accuracy and sensitivity of the drug detection process. Additionally, eliminating matrix peaks effect can prolong the lifetime of the used analytical column to reduce analysis cost in limited resources labs.</p><p id="Par36">Both protein precipitation and liquid-liquid extraction as extraction procedures were tried. Better recoveries were achieved in case of using liquid-liquid extraction by chloroform solvent compared to other solvents such as, hexane, ethyl acetate and diethyl ether.</p></sec><sec id="Sec19"><title>Fluorescence sensitivity</title><p id="Par37">Fluorescence detection was used to detect the analytes in this mixture. Fluorimetric detection is characterized by being more specific to each analyte and sensitive compared to UV-detection, less expensive and more available with respect to mass spectrometry.</p><p id="Par38">FTC exhibits excitation wavelength at 270&#160;nm, emission wavelength at 350&#160;nm and retention time 2.6&#160;min. While DAC has retention time 4.8&#160;min, excitation wavelength at 300&#160;nm and emission wavelength at 380&#160;nm. At retention time 9.9&#160;min LDV was separated having excitation wavelength at 340&#160;nm and emission wavelength at 420&#160;nm.</p><p id="Par39">Changing the excitation and emission wavelengths in a time-programming mode was employed to allow the quantitation of three analytes in the same chromatogram according to the retention time of each drug as shown in Table&#160;1. The analytes were adequately separated under the previously indicated chromatographic conditions.</p></sec></sec><sec id="Sec20"><title>Method validation</title><p id="Par40">The proposed method was validated according to the FDA guidance for bioanalytical method validation<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. The obtained parameters successfully met the defined acceptance criteria.</p><sec id="Sec21"><title>Selectivity</title><p id="Par41">The obtained chromatograms revealed good selectivity of the method. The blank human urine chromatogram in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> (a) and the chromatogram of the spiked samples with the analytes shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> (b) didn&#8217;t show any interfering peaks from the matrix at any of the retention times of the three analytes.</p><p id="Par42">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>(<bold>a</bold>) HPLC chromatogram of blank human urine sample. (<bold>b</bold>) HPLC chromatogram of mixture containing FTC (5000 ng/mL) at &#955;em 350&#160;nm, DAC (45 ng/mL) at &#955;em 380&#160;nm and LDV (20 ng/mL) at &#955;em 420&#160;nm in extracted human urine samples.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e750" position="float" orientation="portrait" xlink:href="41598_2025_7401_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec22"><title>Linearity and sensitivity</title><p id="Par43">The proposed method was linear for each analyte over the concentration ranges (500&#8211;15,000 ng/mL, 1&#8211;50 ng/mL and 10&#8211;100 ng/mL) for FTC, DAC and LDV respectively. The plotted calibration curves revealed correlation coefficients (r) more than 0.999 for each analyte as depicted in Table <xref rid="Tab3" ref-type="table">3</xref> together with other regression parameters.</p><p id="Par44">These concentration ranges were selected according to the urinary excretion profiles of the three analytes FTC, DAC and LDV which are excreted in urine at 86%, 6.6%, and 1% of the administered dose, respectively<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref></sup>. Thus, the approximate expected urine concentrations for each drug are: for FTC 143&#160;mg/L (dose 200&#160;mg once daily), for DAC 3&#160;mg/L (dose 60&#160;mg once daily) and for LDV 0.75&#160;mg/L (dose 90&#160;mg once daily), assuming 1.2&#160;L/day urine output as middle range for healthy adults<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. However, it is impossible to inject these high concentrations into the HPLC because this might exceed the detector response limit resulting in inaccurate results, cause column overload and increase the risk of carryover. Therefore, the selected linear ranges of this proposed method are achieved by approximately 100-fold dilution of collected urine samples which is routinely done in clinical laboratories before urine samples injection into HPLC.</p><p id="Par45">Sensitivity of the method was verified through getting acceptable accuracy and precision (within 20% deviation) for analytes&#8217; LLOQ concentrations as mentioned in accuracy results. The LLOQ samples were 500, 1 and 10 ng/mL for FTC, DAC and LDV, respectively.</p><p id="Par47">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Parameters obtained from emtricitabine (FTC), daclatasvir (DAC) and ledipasvir (LDV) linearity curves.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Emtricitabine (FTC)</th><th align="left" colspan="1" rowspan="1">Daclatasvir (DAC)</th><th align="left" colspan="1" rowspan="1">Ledipasvir (LDV)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Linearity range (ng/mL)</td><td align="left" colspan="1" rowspan="1">500&#8211;15000</td><td align="left" colspan="1" rowspan="1">1&#8211;50</td><td align="left" colspan="1" rowspan="1">10&#8211;100</td></tr><tr><td align="left" colspan="1" rowspan="1">n</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">6</td></tr><tr><td align="left" colspan="1" rowspan="1">Slope</td><td align="left" colspan="1" rowspan="1">103</td><td align="left" colspan="1" rowspan="1">6536.9</td><td align="left" colspan="1" rowspan="1">1732.5</td></tr><tr><td align="left" colspan="1" rowspan="1">Intercept</td><td align="left" colspan="1" rowspan="1">&#8722; 1048.9</td><td align="left" colspan="1" rowspan="1">87,991</td><td align="left" colspan="1" rowspan="1">&#8722; 1659.6</td></tr><tr><td align="left" colspan="1" rowspan="1">Correlation coefficient (r)</td><td align="left" colspan="1" rowspan="1">0.9993</td><td align="left" colspan="1" rowspan="1">0.9995</td><td align="left" colspan="1" rowspan="1">0.9992</td></tr><tr><td align="left" colspan="1" rowspan="1">Lower limit of quantification (LLOQ) (ng/mL)</td><td align="left" colspan="1" rowspan="1">500</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec23"><title>Accuracy and precision</title><p id="Par48">The calculated %recoveries of each analyte by the developed method were demonstrated in Table <xref rid="Tab4" ref-type="table">4</xref>, the intra-day accuracy values of the assay were between 99.13 and 102.12% with a precision of 0.65&#8211;2.95% for emtricitabine. For daclatasvir, the intra-day accuracy ranged from 99.63 to 102.45% with a precision of 0.61&#8211;4.57%. Regarding ledipasvir, the intra-day accuracy varied from 99.86 to 103.49% with a precision of 0.59&#8211;1.33%.</p><p id="Par49">Whereas, results of inter-day accuracy and precision were illustrated in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>; emtricitabine inter-day accuracy values were 99.14-103.22% with a precision of 1.61&#8211;2.86%. While daclatasvir inter-day accuracy values were in the range 100.08-106.72% with a precision of 0.81&#8211;5.69%. For ledipasvir, inter-day accuracy values were 99.36-104.68% with a precision of 0.53&#8211;1.82%. All the results met the acceptance criteria stated by the FDA; results fell within &#177;&#8201;15% of nominal concentration except for the LLOQ where deviation within &#177;&#8201;20% was allowed<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>.</p><p id="Par50">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Accuracy and precision for the HPLC determination of emtricitabine (FTC), Daclatasvir (DAC) and Ledipasvir (LDV) in human urine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7" rowspan="1">Intraday accuracy and precision</th></tr><tr><th align="left" rowspan="2" colspan="1">Sample</th><th align="left" colspan="2" rowspan="1">Emtricitabine (FTC)</th><th align="left" colspan="2" rowspan="1">Daclatasvir (DAC)</th><th align="left" colspan="2" rowspan="1">Ledipasvir (LDV)</th></tr><tr><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">LLOQ</td><td align="left" colspan="1" rowspan="1">500</td><td align="left" colspan="1" rowspan="1">102.12&#8201;&#177;&#8201;1.14</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">102.46&#8201;&#177;&#8201;4.57</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">103.49&#8201;&#177;&#8201;1.19</td></tr><tr><td align="left" colspan="1" rowspan="1">QCL</td><td align="left" colspan="1" rowspan="1">1500</td><td align="left" colspan="1" rowspan="1">99.78&#8201;&#177;&#8201;2.32</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">101.53&#8201;&#177;&#8201;3.95</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">101.39&#8201;&#177;&#8201;1.33</td></tr><tr><td align="left" colspan="1" rowspan="1">QCM</td><td align="left" colspan="1" rowspan="1">7000</td><td align="left" colspan="1" rowspan="1">99.13&#8201;&#177;&#8201;0.65</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">101.42&#8201;&#177;&#8201;3.04</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">99.86&#8201;&#177;&#8201;0.59</td></tr><tr><td align="left" colspan="1" rowspan="1">QCH</td><td align="left" colspan="1" rowspan="1">13,000</td><td align="left" colspan="1" rowspan="1">101.69&#8201;&#177;&#8201;2.95</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">99.63&#8201;&#177;&#8201;0.61</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">97.92&#8201;&#177;&#8201;0.97</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7" rowspan="1">Inter-day accuracy and precision</th></tr><tr><th align="left" rowspan="2" colspan="1">Sample</th><th align="left" colspan="2" rowspan="1">Emtricitabine (FTC)</th><th align="left" colspan="2" rowspan="1">Daclatasvir (DAC)</th><th align="left" colspan="2" rowspan="1">Ledipasvir (LDV)</th></tr><tr><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177;% RSD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">LLOQ</td><td align="left" colspan="1" rowspan="1">500</td><td align="left" colspan="1" rowspan="1">103.22&#8201;&#177;&#8201;1.61</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">106.72&#8201;&#177;&#8201;1.35</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">104.68&#8201;&#177;&#8201;1.82</td></tr><tr><td align="left" colspan="1" rowspan="1">QCL</td><td align="left" colspan="1" rowspan="1">1500</td><td align="left" colspan="1" rowspan="1">102.42&#8201;&#177;&#8201;2.86</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">105.64&#8201;&#177;&#8201;5.69</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">101.48&#8201;&#177;&#8201;0.53</td></tr><tr><td align="left" colspan="1" rowspan="1">QCM</td><td align="left" colspan="1" rowspan="1">7000</td><td align="left" colspan="1" rowspan="1">99.30&#8201;&#177;&#8201;1.70</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">100.08&#8201;&#177;&#8201;1.33</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">99.36&#8201;&#177;&#8201;1.49</td></tr><tr><td align="left" colspan="1" rowspan="1">QCH</td><td align="left" colspan="1" rowspan="1">13,000</td><td align="left" colspan="1" rowspan="1">99.14&#8201;&#177;&#8201;1.99</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">100.51&#8201;&#177;&#8201;0.81</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">97.65&#8201;&#177;&#8201;1.54</td></tr></tbody></table><table-wrap-foot><p>*Mean of five determinations.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec24"><title>Recovery</title><p id="Par51">The extraction efficiency of the method for the studied analytes was assessed by determining the recoveries of QC samples (QCL, QCM and QCH) as shown in Table <xref rid="Tab5" ref-type="table">5</xref>. The extraction recovery values were 97.9-99.54% with %RSD 1.14&#8211;3.21% for emtricitabine. In case of daclatasvir extraction recovery values were 98.78-104.17% with %RSD 0.96&#8211;2.45%. For ledipasvir, extraction recovery values ranged from 98.49 to 100.96% with %RSD of 0.84&#8211;1.81%. These results indicate good extraction recovery by chloroform proving the efficiency of the used extraction method.</p><p id="Par52">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Recovery results for HPLC determination of emtricitabine (FTC), Daclatasvir (DAC) and Ledipasvir (LDV).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="2" rowspan="1">Emtricitabine (FTC)</th><th align="left" colspan="2" rowspan="1">Daclatasvir (DAC)</th><th align="left" colspan="2" rowspan="1">Ledipasvir (LDV)</th></tr><tr><th align="left" colspan="1" rowspan="1">Sample</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">QCL</td><td align="left" colspan="1" rowspan="1">1500</td><td align="left" colspan="1" rowspan="1">98.68&#8201;&#177;&#8201;3.21</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">104.17&#8201;&#177;&#8201;2.45</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">100.96&#8201;&#177;&#8201;0.84</td></tr><tr><td align="left" colspan="1" rowspan="1">QCM</td><td align="left" colspan="1" rowspan="1">7000</td><td align="left" colspan="1" rowspan="1">97.90&#8201;&#177;&#8201;1.14</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">101.16&#8201;&#177;&#8201;2.01</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">99.86&#8201;&#177;&#8201;0.89</td></tr><tr><td align="left" colspan="1" rowspan="1">QCH</td><td align="left" colspan="1" rowspan="1">13,000</td><td align="left" colspan="1" rowspan="1">99.54&#8201;&#177;&#8201;3.47</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">98.78&#8201;&#177;&#8201;0.96</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">98.49&#8201;&#177;&#8201;1.81</td></tr></tbody></table><table-wrap-foot><p>*Mean of five determinations.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec25"><title>Stability</title><p id="Par53">Freeze-thaw, bench top and processed sample stability results are illustrated in Table&#160;<xref rid="Tab6" ref-type="table">6</xref>. Data revealed that %recoveries were in the accepted range&#8201;&#177;&#8201;15% indicating that the QC samples were stable at the tested conditions.</p><p id="Par54">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Stability results of emtricitabine (FTC), Daclatasvir (DAC) and Ledipasvir (LDV) in human urine under different stability assessment conditions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7" rowspan="1">Freeze-thaw stability**</th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="2" rowspan="1">Emtricitabine (FTC)</th><th align="left" colspan="2" rowspan="1">Daclatasvir (DAC)</th><th align="left" colspan="2" rowspan="1">Ledipasvir (LDV)</th></tr><tr><th align="left" colspan="1" rowspan="1">Sample</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">QCL</td><td align="left" colspan="1" rowspan="1">1500</td><td align="left" colspan="1" rowspan="1">103.94&#8201;&#177;&#8201;1.01</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">104.83&#8201;&#177;&#8201;4.38</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">101.89&#8201;&#177;&#8201;0.87</td></tr><tr><td align="left" colspan="1" rowspan="1">QCH</td><td align="left" colspan="1" rowspan="1">13,000</td><td align="left" colspan="1" rowspan="1">98.21&#8201;&#177;&#8201;2.09</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">100.07&#8201;&#177;&#8201;1.13</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">98.81&#8201;&#177;&#8201;2.20</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7" rowspan="1">Bench top stability</th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="2" rowspan="1">Emtricitabine (FTC)</th><th align="left" colspan="2" rowspan="1">Daclatasvir (DAC)</th><th align="left" colspan="2" rowspan="1">Ledipasvir (LDV)</th></tr><tr><th align="left" colspan="1" rowspan="1">Sample</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">QCL</td><td align="left" colspan="1" rowspan="1">1500</td><td align="left" colspan="1" rowspan="1">103.13&#8201;&#177;&#8201;0.77</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">103.96&#8201;&#177;&#8201;2.69</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">101.85&#8201;&#177;&#8201;0.62</td></tr><tr><td align="left" colspan="1" rowspan="1">QCH</td><td align="left" colspan="1" rowspan="1">13,000</td><td align="left" colspan="1" rowspan="1">98.54&#8201;&#177;&#8201;1.96</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">98.92&#8201;&#177;&#8201;1.44</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">97.82&#8201;&#177;&#8201;1.80</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7" rowspan="1">Processed sample stability</th></tr><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="2" rowspan="1">Emtricitabine (FTC)</th><th align="left" colspan="2" rowspan="1">Daclatasvir (DAC)</th><th align="left" colspan="2" rowspan="1">Ledipasvir (LDV)</th></tr><tr><th align="left" colspan="1" rowspan="1">Sample</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th><th align="left" colspan="1" rowspan="1">Conc. (ng/mL)</th><th align="left" colspan="1" rowspan="1">Mean %recovery* &#177; %RSD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">QCL</td><td align="left" colspan="1" rowspan="1">1500</td><td align="left" colspan="1" rowspan="1">103.23&#8201;&#177;&#8201;1.28</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">103.16&#8201;&#177;&#8201;5.58</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">100.26&#8201;&#177;&#8201;2.58</td></tr><tr><td align="left" colspan="1" rowspan="1">QCH</td><td align="left" colspan="1" rowspan="1">13,000</td><td align="left" colspan="1" rowspan="1">96.33&#8201;&#177;&#8201;3.47</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">100.31&#8201;&#177;&#8201;1.74</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">97.85&#8201;&#177;&#8201;0.77</td></tr></tbody></table><table-wrap-foot><p>*Mean of three determinations.</p><p>**Mean of three freeze-thaw cycles.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec26"><title>Robustness and system suitability parameters</title><p id="Par55">Table&#160;<xref rid="Tab7" ref-type="table">7</xref> summarizes robustness results the low %RSD reflects method robustness after applying the mentioned changes in flow rate, buffer pH and mobile phase composition. A paired t-test was conducted to compare recoveries for each analyte before and after conditions change. The calculated <italic toggle="yes">t</italic> values (shown in Table&#160;<xref rid="Tab7" ref-type="table">7</xref>) are less than the tabulated one (for <italic toggle="yes">n</italic>&#8201;=&#8201;6, <italic toggle="yes">t</italic> tabulated&#8201;=&#8201;2.57, considering 95% confidence interval) which indicates that no significant difference was observed before and after changes made to asses robustness. Hence, the proposed method is robust based on changes made in flow rate, buffer pH and organic strength. The effect of the applied changes on chromatographic performance was evaluated. Increasing the flow rate to 1.1 mL/min decreased the retention times of the three analytes by approximately 0.2&#160;min. While, decreasing methanol concentration in mobile phase by 2% decreased resolution to be 4.66 and 7.12 for DAC and LCV peaks, respectively. Other changes didn&#8217;t show observed variations in method performance.</p><p id="Par56">Moreover, system suitability parameters as capacity factor, number of theoretical plates, resolution were calculated. Then compared to guideline values and found to be satisfactory showing good performance of the optimized system as demonstrated in Table&#160;<xref rid="Tab8" ref-type="table">8</xref>.</p><p id="Par57">
<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table 7</label><caption><p>Robustness results of HPLC determination of each analyte QCM (700, 25 and 50 ng/ml for FTC, DAC and LDV, respectively) in human urine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Emtricitabine (FTC)</th><th align="left" colspan="1" rowspan="1">Daclatasvir (DAC)</th><th align="left" colspan="1" rowspan="1">Ledipasvir (LDV)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Flow rate (&#177;&#8201;0.1 mL/min)</td><td align="left" colspan="1" rowspan="1">%RSD</td><td char="." align="char" colspan="1" rowspan="1">0.65</td><td char="." align="char" colspan="1" rowspan="1">0.36</td><td char="." align="char" colspan="1" rowspan="1">0.79</td></tr><tr><td align="left" colspan="1" rowspan="1">t value</td><td char="." align="char" colspan="1" rowspan="1">0.61</td><td char="." align="char" colspan="1" rowspan="1">0.54</td><td char="." align="char" colspan="1" rowspan="1">0.67</td></tr><tr><td align="left" rowspan="2" colspan="1">Buffer pH (&#177;&#8201;0.2)</td><td align="left" colspan="1" rowspan="1">%RSD</td><td char="." align="char" colspan="1" rowspan="1">1.40</td><td char="." align="char" colspan="1" rowspan="1">0.65</td><td char="." align="char" colspan="1" rowspan="1">0.47</td></tr><tr><td align="left" colspan="1" rowspan="1">t value</td><td char="." align="char" colspan="1" rowspan="1">0.87</td><td char="." align="char" colspan="1" rowspan="1">0.63</td><td char="." align="char" colspan="1" rowspan="1">0.55</td></tr><tr><td align="left" rowspan="2" colspan="1">Organic strength (&#177;&#8201;2%) in methanol</td><td align="left" colspan="1" rowspan="1">%RSD</td><td char="." align="char" colspan="1" rowspan="1">1.39</td><td char="." align="char" colspan="1" rowspan="1">1.01</td><td char="." align="char" colspan="1" rowspan="1">0.57</td></tr><tr><td align="left" colspan="1" rowspan="1">t value</td><td char="." align="char" colspan="1" rowspan="1">0.84</td><td char="." align="char" colspan="1" rowspan="1">0.76</td><td char="." align="char" colspan="1" rowspan="1">0.59</td></tr></tbody></table></table-wrap>
</p><p id="Par58">
<table-wrap id="Tab8" position="float" orientation="portrait"><label>Table 8</label><caption><p>System suitability parameters of HPLC determination of emtricitabine (FTC), Daclatasvir (DAC) and Ledipasvir (LDV) in human urine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameters</th><th align="left" colspan="1" rowspan="1">Emtricitabine (FTC)</th><th align="left" colspan="1" rowspan="1">Daclatasvir (DAC)</th><th align="left" colspan="1" rowspan="1">Ledipasvir (LDV)</th><th align="left" colspan="1" rowspan="1">Reference values<sup>41</sup></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Retention time (min)</td><td align="left" colspan="1" rowspan="1">2.60</td><td align="left" colspan="1" rowspan="1">4.80</td><td align="left" colspan="1" rowspan="1">9.89</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Tailing factor (T)</td><td align="left" colspan="1" rowspan="1">1.33</td><td align="left" colspan="1" rowspan="1">1.36</td><td align="left" colspan="1" rowspan="1">1.15</td><td align="left" colspan="1" rowspan="1">&#8804;&#8201;2</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of theoretical plates (N)</td><td align="left" colspan="1" rowspan="1">2578</td><td align="left" colspan="1" rowspan="1">3366</td><td align="left" colspan="1" rowspan="1">3326</td><td align="left" colspan="1" rowspan="1">&gt;&#8201;2000</td></tr><tr><td align="left" colspan="1" rowspan="1">Capacity factor (k&#8217;)</td><td align="left" colspan="1" rowspan="1">1.17</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">7.25</td><td align="left" colspan="1" rowspan="1">1&#8211;10</td></tr><tr><td align="left" colspan="1" rowspan="1">Resolution (R<sub>s</sub>)</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">4.73</td><td align="left" colspan="1" rowspan="1">7.32</td><td align="left" colspan="1" rowspan="1">&gt;&#8201;2</td></tr><tr><td align="left" colspan="1" rowspan="1">Selectivity (&#945;)</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">2.56</td><td align="left" colspan="1" rowspan="1">2.42</td><td align="left" colspan="1" rowspan="1">1&#8211;5</td></tr></tbody></table></table-wrap>
</p></sec></sec></sec><sec id="Sec27"><title>Conclusion</title><p id="Par59">The three co-administered drugs; FTC, DAC and LDV used for HIV/HCV co-infection were quantified in human urine by our validated method. It was validated according to the FDA bioanalytical validation guidelines. The method achieved good accuracy, precision and sensitivity over wide concentration range. It is the first reported method for simultaneous determination of the studied drugs. We propose applying the method for routine urine analysis of HIV/HCV co-infected patients aiming to monitoring the tested drugs levels and ensuring patients&#8217; drug adherence. The significance of HIV patients&#8217; obedience to their drug regimen highly impacts the global public health and lessens threats to the communities.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>A.A.Y.: conceptualization, methodology, investigation, formal analysis, writing original draft. N.M.: conceptualization, formal analysis, review and editing. L.A.H.: conceptualization, validation, review and editing. A.M.E-K.: conceptualization, supervision, project administration.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data is provided within the manuscript and any other required details can be furnished by the corresponding author upon request.</p></notes><notes><title>Declarations</title><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par60">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>5. References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Ghazy, R. M., Awaidy, A. &amp; Taha, S. H. S. N. Trends of HIV indicators in Egypt from 1990 to 2021: time-series analysis and forecast toward UNAIDS 90-90-90 targets. <italic toggle="yes">BMC Public Health</italic><bold>23</bold> (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-023-15490-5</pub-id><pub-id pub-id-type="pmcid">PMC10066021</pub-id><pub-id pub-id-type="pmid">37005670</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Arends, J. E. et al. Natural history and treatment of HCV/HIV coinfection: is it time to change paradigms? <bold>63</bold>, 1254&#8211;1262 (2015).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2015.06.034</pub-id><pub-id pub-id-type="pmid">26186987</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Waked, I. et al. Screening and treatment program to eliminate hepatitis C in Egypt. <italic toggle="yes">N. Engl. J. Med.</italic><bold>382</bold> (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMsr1912628</pub-id><pub-id pub-id-type="pmid">32187475</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Zuckerman, A. D. et al. Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: does coinfection really matter? <italic toggle="yes">PLoS ONE</italic><bold>14</bold> (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0225434</pub-id><pub-id pub-id-type="pmcid">PMC6872158</pub-id><pub-id pub-id-type="pmid">31751399</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreoni</surname><given-names>M</given-names></name><etal/></person-group><article-title>HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2012</year><volume>16</volume><fpage>1473</fpage><lpage>1483</lpage><pub-id pub-id-type="pmid">23111959</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Andreoni, M. et al. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. <italic toggle="yes">Eur. Rev. Med. Pharmacol. Sci.</italic><bold>16</bold>, 1473&#8211;1483 (2012).<pub-id pub-id-type="pmid">23111959</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyles</surname><given-names>DL</given-names></name><name name-style="western"><surname>Sulkowski</surname><given-names>MS</given-names></name><name name-style="western"><surname>Dieterich</surname><given-names>D</given-names></name></person-group><article-title>Management of hepatitis C/HIV coinfection in the era of highly effective hepatitis C virus Direct-Acting antiviral therapy</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>63</volume><fpage>S3</fpage><lpage>S11</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw219</pub-id><pub-id pub-id-type="pmid">27363438</pub-id><pub-id pub-id-type="pmcid">PMC4928450</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Wyles, D. L., Sulkowski, M. S. &amp; Dieterich, D. Management of hepatitis C/HIV coinfection in the era of highly effective hepatitis C virus Direct-Acting antiviral therapy. <italic toggle="yes">Clin. Infect. Dis.</italic><bold>63</bold>, S3&#8211;S11 (2016).<pub-id pub-id-type="pmid">27363438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciw219</pub-id><pub-id pub-id-type="pmcid">PMC4928450</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Bunchorntavakul, C. &amp; Reddy, K. R. Review article: The efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. <italic toggle="yes">Aliment. Pharmacol. Therap.</italic><bold>42</bold>, 258&#8211;272. 10.1111/apt.13264016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.13264</pub-id><pub-id pub-id-type="pmid">26014906</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Ledipasvir/Sofosbuvir</surname></name></person-group><article-title>A review in chronic hepatitis C</article-title><source>Drugs</source><year>2018</year><volume>78</volume><fpage>245</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1007/s40265-018-0864-z</pub-id><pub-id pub-id-type="pmid">29380288</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Scott, L. J. &amp; Ledipasvir/Sofosbuvir A review in chronic hepatitis C. <italic toggle="yes">Drugs</italic><bold>78</bold>, 245&#8211;256 (2018).<pub-id pub-id-type="pmid">29380288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-018-0864-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Oloruntoba, O. &amp; Muir, A. J. Integrating daclatasvir into hepatitis C therapy. <italic toggle="yes">Clin. Liver Dis.</italic><bold>7</bold>, 1&#8211;4. 10.1002/cld.524 (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cld.524</pub-id><pub-id pub-id-type="pmcid">PMC6490247</pub-id><pub-id pub-id-type="pmid">31041015</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younossi</surname><given-names>ZM</given-names></name><etal/></person-group><article-title>Sofosbuvir and Ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus</article-title><source>J. Viral Hepat.</source><year>2016</year><volume>23</volume><fpage>857</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1111/jvh.12554</pub-id><pub-id pub-id-type="pmid">27291391</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Younossi, Z. M. et al. Sofosbuvir and Ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. <italic toggle="yes">J. Viral Hepat.</italic><bold>23</bold>, 857&#8211;865 (2016).<pub-id pub-id-type="pmid">27291391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvh.12554</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Modrzejewski, K. A., Herman, R. A. &amp; Emtricitabine A once-daily nucleoside reverse transcriptase inhibitor. <italic toggle="yes">Ann. Pharmacother.</italic><bold>38</bold>, 1006&#8211;1014. 10.1345/aph.1D302 (2004).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1345/aph.1D302</pub-id><pub-id pub-id-type="pmid">15121999</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Pharmacological considerations for Tenofovir and emtricitabine to prevent HIV infection</article-title><source>J. Antimicrob. Chemother.</source><year>2011</year><volume>66</volume><fpage>240</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1093/jac/dkq447</pub-id><pub-id pub-id-type="pmid">21118913</pub-id><pub-id pub-id-type="pmcid">PMC3019086</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Anderson, P. L. et al. Pharmacological considerations for Tenofovir and emtricitabine to prevent HIV infection. <italic toggle="yes">J. Antimicrob. Chemother.</italic><bold>66</bold>, 240&#8211;250 (2011).<pub-id pub-id-type="pmid">21118913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkq447</pub-id><pub-id pub-id-type="pmcid">PMC3019086</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Runja</surname><given-names>C</given-names></name><name name-style="western"><surname>Ravi Kumar</surname><given-names>P</given-names></name><name name-style="western"><surname>Avanapu</surname><given-names>SR</given-names></name></person-group><article-title>A validated stability indicating RP-HPLC method for the determination of emtricitabine, Tenofovir disoproxil fumarate, elvitegravir and cobicistat in pharmaceutical dosage form</article-title><source>J. Chromatogr. Sci.</source><year>2016</year><volume>54</volume><fpage>759</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1093/chromsci/bmw004</pub-id><pub-id pub-id-type="pmid">26865655</pub-id><pub-id pub-id-type="pmcid">PMC4890450</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Runja, C., Ravi Kumar, P. &amp; Avanapu, S. R. A validated stability indicating RP-HPLC method for the determination of emtricitabine, Tenofovir disoproxil fumarate, elvitegravir and cobicistat in pharmaceutical dosage form. <italic toggle="yes">J. Chromatogr. Sci.</italic><bold>54</bold>, 759&#8211;764 (2016).<pub-id pub-id-type="pmid">26865655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/chromsci/bmw004</pub-id><pub-id pub-id-type="pmcid">PMC4890450</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul Sattar</surname><given-names>MD</given-names></name><name name-style="western"><surname>Achanta</surname><given-names>S</given-names></name></person-group><article-title>Analytical method development and validation for the determination of emtricitabine and Tenofovir disoproxil fumarate using reverse phase HPLC method in bulk and tablet dosage form</article-title><source>J. Pharm. Sci. Res.</source><year>2018</year><volume>10</volume><fpage>1207</fpage><lpage>1212</lpage></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Abdul Sattar, M. D. &amp; Achanta, S. Analytical method development and validation for the determination of emtricitabine and Tenofovir disoproxil fumarate using reverse phase HPLC method in bulk and tablet dosage form. <italic toggle="yes">J. Pharm. Sci. Res.</italic><bold>10</bold>, 1207&#8211;1212 (2018).</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kokkirala</surname><given-names>TK</given-names></name><name name-style="western"><surname>Suryakala</surname><given-names>D</given-names></name></person-group><article-title>RP-HPLC method development and validation for the Estimation of emtricitabine, bictegravir and Tenofovir Alafenamide in bulk and pharmaceutical dosage form</article-title><source>J. Taibah Univ. Sci.</source><year>2019</year><volume>13</volume><fpage>1137</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1080/16583655.2019.1689601</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kokkirala, T. K. &amp; Suryakala, D. RP-HPLC method development and validation for the Estimation of emtricitabine, bictegravir and Tenofovir Alafenamide in bulk and pharmaceutical dosage form. <italic toggle="yes">J. Taibah Univ. Sci.</italic><bold>13</bold>, 1137&#8211;1146 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>AbdelHay</surname><given-names>MH</given-names></name><name name-style="western"><surname>Gazy</surname><given-names>AA</given-names></name><name name-style="western"><surname>Shaalan</surname><given-names>RA</given-names></name><name name-style="western"><surname>Ashour</surname><given-names>HK</given-names></name></person-group><article-title>Selective RP-HPLC DAD method for determination of Tenofovir fumarate and emtricitabine in bulk powder and in tablets</article-title><source>Acta Chromatogr.</source><year>2015</year><volume>27</volume><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1556/AChrom.27.2015.1.4</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">AbdelHay, M. H., Gazy, A. A., Shaalan, R. A. &amp; Ashour, H. K. Selective RP-HPLC DAD method for determination of Tenofovir fumarate and emtricitabine in bulk powder and in tablets. <italic toggle="yes">Acta Chromatogr.</italic><bold>27</bold>, 41&#8211;54 (2015).</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Droste</surname><given-names>JAH</given-names></name><name name-style="western"><surname>Aarnoutse</surname><given-names>RE</given-names></name><name name-style="western"><surname>Burger</surname><given-names>DM</given-names></name></person-group><article-title>Determination of emtricitabine in human plasma using HPLC with fluorometric detection</article-title><source>J. Liq Chromatogr. Relat. Technol.</source><year>2007</year><volume>30</volume><fpage>2769</fpage><lpage>2778</lpage><pub-id pub-id-type="doi">10.1080/10826070701560900</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Droste, J. A. H., Aarnoutse, R. E. &amp; Burger, D. M. Determination of emtricitabine in human plasma using HPLC with fluorometric detection. <italic toggle="yes">J. Liq Chromatogr. Relat. Technol.</italic><bold>30</bold>, 2769&#8211;2778 (2007).</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Fong, I. W. <italic toggle="yes">New Antiretroviral Agents for HIV Infection</italic> 161&#8211;182. 10.1007/978-3-031-26078-0_12 (2023).</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCormack</surname><given-names>PL</given-names></name><name name-style="western"><surname>Daclatasvir</surname></name></person-group><article-title>A review of its use in adult patients with chronic hepatitis C virus infection</article-title><source>Drugs</source><year>2015</year><volume>75</volume><fpage>515</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1007/s40265-015-0362-5</pub-id><pub-id pub-id-type="pmid">25721433</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">McCormack, P. L. &amp; Daclatasvir A review of its use in adult patients with chronic hepatitis C virus infection. <italic toggle="yes">Drugs</italic><bold>75</bold>, 515&#8211;524 (2015).<pub-id pub-id-type="pmid">25721433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-015-0362-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afdhal</surname><given-names>N</given-names></name><etal/></person-group><article-title>Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>1889</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1402454</pub-id><pub-id pub-id-type="pmid">24725239</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Afdhal, N. et al. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection. <italic toggle="yes">N. Engl. J. Med.</italic><bold>370</bold>, 1889&#8211;1898 (2014).<pub-id pub-id-type="pmid">24725239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1402454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassib</surname><given-names>ST</given-names></name><name name-style="western"><surname>Taha</surname><given-names>EA</given-names></name><name name-style="western"><surname>Elkady</surname><given-names>EF</given-names></name><name name-style="western"><surname>Barakat</surname><given-names>GH</given-names></name></person-group><article-title>Reversed-Phase liquid chromatographic method for determination of Daclatasvir dihydrochloride and study of its degradation behavior</article-title><source>Chromatographia</source><year>2017</year><volume>80</volume><fpage>1101</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1007/s10337-017-3321-3</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Hassib, S. T., Taha, E. A., Elkady, E. F. &amp; Barakat, G. H. Reversed-Phase liquid chromatographic method for determination of Daclatasvir dihydrochloride and study of its degradation behavior. <italic toggle="yes">Chromatographia</italic><bold>80</bold>, 1101&#8211;1107 (2017).</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saleh</surname><given-names>H</given-names></name><name name-style="western"><surname>Ragab</surname><given-names>GH</given-names></name><name name-style="western"><surname>Othman</surname><given-names>MA</given-names></name></person-group><article-title>Stability indicating HPLC method development and validation for determination of Daclatasvir in pure and tablets dosage forms</article-title><source>Indo Am. J. Pharm. Sci.</source><year>2016</year><volume>3</volume><fpage>1565</fpage><lpage>1572</lpage></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Saleh, H., Ragab, G. H. &amp; Othman, M. A. Stability indicating HPLC method development and validation for determination of Daclatasvir in pure and tablets dosage forms. <italic toggle="yes">Indo Am. J. Pharm. Sci.</italic><bold>3</bold>, 1565&#8211;1572 (2016).</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Devilal, J. et al. <italic toggle="yes">World J. Pharm. Pharm. Sci.</italic><bold>5</bold>, 1312&#8211;1321 (2016).</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Stability indicating RP-HPLC method for Estimation of potential impurities in Ledipasvir and characterization of a new degradation impurity</article-title><source>J. Chromatogr. Sci.</source><year>2018</year><volume>56</volume><fpage>383</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1093/chromsci/bmx084</pub-id><pub-id pub-id-type="pmid">29474520</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Kumar, S. Stability indicating RP-HPLC method for Estimation of potential impurities in Ledipasvir and characterization of a new degradation impurity. <italic toggle="yes">J. Chromatogr. Sci.</italic><bold>56</bold>, 383&#8211;395 (2018).<pub-id pub-id-type="pmid">29474520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/chromsci/bmx084</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">El-Kassem, M., Hassouna, M., Abdelrahman, M. M. &amp; Mohamed, M. A. <italic toggle="yes">Assay and Dissolution Methods Development and Validation for Simultaneous Determination of Sofosbuvir and Ledipasvir by RP-HPLC Method in Tablet Dosage Forms</italic>, vol. 1 (2017).</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Zaman, B., Siddique, F. &amp; Hassan, W. RP-HPLC method for simultaneous determination of sofosbuvir and ledipasvir in tablet dosage form and its application to in vitro dissolution studies. <italic toggle="yes">Chromatographia</italic><bold>79</bold>, 1605&#8211;1613 (2016).</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">EL-Shorbagy, H. I., Elsebaei, F., Hammad, S. F. &amp; El-Brashy, A. M. A green stability-indicating RP-HPLC-UV method using factorial design for determination of ribavirin, Sofosbuvir and ledipasvir: application to average content, acid degradation kinetics and in vitro drug interactions study. <italic toggle="yes">Microchem. J.</italic><bold>158</bold> (2020).</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Mohamed, H. M., Saad, A. S., Morsi, A. M. &amp; Essam, H. M. Green RP-HPLC method for simultaneous determination of sofosbuvir, ledipasvir, velpatasvir antivirals and beyond in their bulk material and co-formulated products. <italic toggle="yes">Microchem. J.</italic><bold>186</bold> (2023).</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadie</surname><given-names>M</given-names></name><name name-style="western"><surname>Mostafa</surname><given-names>S</given-names></name><name name-style="western"><surname>El.Adl</surname><given-names>S</given-names></name></person-group><article-title>Development andvalidation of a new, Simple-HPLC method for simultaneous determination ofsofosbuvir, Daclatasvir and ribavirin in tablet dosage form</article-title><source>IOSR J. Pharm. Biol. Sci.</source><year>2017</year><volume>12</volume><fpage>60</fpage><lpage>68</lpage></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Wadie, M., Mostafa, S. &amp; El.Adl, S. Development andvalidation of a new, Simple-HPLC method for simultaneous determination ofsofosbuvir, Daclatasvir and ribavirin in tablet dosage form. <italic toggle="yes">IOSR J. Pharm. Biol. Sci.</italic><bold>12</bold>, 60&#8211;68 (2017).</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamal</surname><given-names>AH</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>NS</given-names></name><name name-style="western"><surname>Mabrouk</surname><given-names>MM</given-names></name><name name-style="western"><surname>Bebawy</surname><given-names>LI</given-names></name><name name-style="western"><surname>Mekky</surname><given-names>MA</given-names></name></person-group><article-title>Development and validation of HPLC fluorescence and UPLC/DAD stability-indicating methods for determination of hepatitis C antiviral agent Daclatasvir</article-title><source>J. AOAC Int.</source><year>2019</year><volume>102</volume><fpage>1125</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.5740/jaoacint.18-0344</pub-id><pub-id pub-id-type="pmid">30940292</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Kamal, A. H., Ismail, N. S., Mabrouk, M. M., Bebawy, L. I. &amp; Mekky, M. A. Development and validation of HPLC fluorescence and UPLC/DAD stability-indicating methods for determination of hepatitis C antiviral agent Daclatasvir. <italic toggle="yes">J. AOAC Int.</italic><bold>102</bold>, 1125&#8211;1131 (2019).<pub-id pub-id-type="pmid">30940292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5740/jaoacint.18-0344</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo-Zeid</surname><given-names>MN</given-names></name><name name-style="western"><surname>Atia</surname><given-names>NN</given-names></name><name name-style="western"><surname>El-Gizawy</surname><given-names>SM</given-names></name><name name-style="western"><surname>El-Shaboury</surname><given-names>SR</given-names></name></person-group><article-title>Ultrasensitive spectrofluorimetric method for rapid determination of Daclatasvir and Ledipasvir in human plasma and pharmaceutical formulations</article-title><source>J. Pharm. Biomed. Anal.</source><year>2018</year><volume>152</volume><fpage>155</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2018.01.038</pub-id><pub-id pub-id-type="pmid">29414007</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Abo-Zeid, M. N., Atia, N. N., El-Gizawy, S. M. &amp; El-Shaboury, S. R. Ultrasensitive spectrofluorimetric method for rapid determination of Daclatasvir and Ledipasvir in human plasma and pharmaceutical formulations. <italic toggle="yes">J. Pharm. Biomed. Anal.</italic><bold>152</bold>, 155&#8211;164 (2018).<pub-id pub-id-type="pmid">29414007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpba.2018.01.038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Saag, M. S. <italic toggle="yes">Emtricitabine, a New Antiretroviral Agent with Activity against HIV and Hepatitis B Virus</italic>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://academic.oup.com/cid/article/42/1/126/393512">https://academic.oup.com/cid/article/42/1/126/393512</ext-link> (2006).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/498348</pub-id><pub-id pub-id-type="pmid">16323102</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Haaland, R. E. et al. Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis. <italic toggle="yes">AIDS</italic><bold>31</bold>, 1647&#8211;1650. 10.1097/QAD.0000000000001551 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAD.0000000000001551</pub-id><pub-id pub-id-type="pmcid">PMC5541255</pub-id><pub-id pub-id-type="pmid">28657968</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Smolders, E. J. et al. Viral hepatitis C therapy: Pharmacokinetic and pharmacodynamic considerations: A 2019 update. <italic toggle="yes">Clin. Pharmacokinet.</italic><bold>58</bold>, 1237&#8211;1263. 10.1007/s40262-019-00774-0 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-019-00774-0</pub-id><pub-id pub-id-type="pmcid">PMC6768915</pub-id><pub-id pub-id-type="pmid">31114957</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cressey</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Plasma pharmacokinetics and urinary excretion of Tenofovir following cessation in adults with controlled levels of adherence to Tenofovir disoproxil fumarate</article-title><source>Int. J. Infect. Dis.</source><year>2020</year><volume>97</volume><fpage>365</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.06.037</pub-id><pub-id pub-id-type="pmid">32553717</pub-id><pub-id pub-id-type="pmcid">PMC7392195</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Cressey, T. R. et al. Plasma pharmacokinetics and urinary excretion of Tenofovir following cessation in adults with controlled levels of adherence to Tenofovir disoproxil fumarate. <italic toggle="yes">Int. J. Infect. Dis.</italic><bold>97</bold>, 365&#8211;370 (2020).<pub-id pub-id-type="pmid">32553717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2020.06.037</pub-id><pub-id pub-id-type="pmcid">PMC7392195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upadhyay</surname><given-names>SM</given-names></name><name name-style="western"><surname>Dhok</surname><given-names>A</given-names></name><name name-style="western"><surname>Quazi</surname><given-names>ZS</given-names></name></person-group><article-title>High-performance liquid chromatography based methods for determination of antitubercular drugs in urine samples: A scoping review</article-title><source>J. Clin. Diagn. Res.</source><year>2023</year><pub-id pub-id-type="doi">10.7860/jcdr/2023/66092.18542</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Upadhyay, S. M., Dhok, A. &amp; Quazi, Z. S. High-performance liquid chromatography based methods for determination of antitubercular drugs in urine samples: A scoping review. <italic toggle="yes">J. Clin. Diagn. Res.</italic>10.7860/jcdr/2023/66092.18542 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmer</surname><given-names>D</given-names></name><name name-style="western"><surname>NewUS</surname></name></person-group><article-title>FDA draft guidance on bioanalyticalmethod validation versus current FDA and EMA guidelines: chromatographic methods and ISR</article-title><source>Bioanalysis</source><year>2014</year><volume>6</volume><issue>1</issue><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.4155/bio.13.298</pub-id><pub-id pub-id-type="pmid">24256335</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Zimmer, D. &amp; NewUS FDA draft guidance on bioanalyticalmethod validation versus current FDA and EMA guidelines: chromatographic methods and ISR. <italic toggle="yes">Bioanalysis</italic><bold>6</bold> (1), 13&#8211;19 (2014).<pub-id pub-id-type="pmid">24256335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/bio.13.298</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">US Food and Drug Administration. <italic toggle="yes">Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration</italic> (Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001).</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Stratigou, I. C. et al. Homogeneous liquid liquid extraction using salt as mass separating agent for the ultra high pressure liquid chromatographic determination of doxorubicin in human urine. <italic toggle="yes">Microchem. J.</italic><bold>158</bold> (2020).</mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacEdo</surname><given-names>E</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>R</given-names></name><name name-style="western"><surname>Claure-Del Granado</surname><given-names>R</given-names></name><name name-style="western"><surname>Fedullo</surname><given-names>P</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>RL</given-names></name></person-group><article-title>Defining urine output criterion for acute kidney injury in critically ill patients</article-title><source>Nephrol. Dialysis Transplantation</source><year>2011</year><volume>26</volume><fpage>509</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq332</pub-id><pub-id pub-id-type="pmcid">PMC3108356</pub-id><pub-id pub-id-type="pmid">20562094</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">MacEdo, E., Malhotra, R., Claure-Del Granado, R., Fedullo, P. &amp; Mehta, R. L. Defining urine output criterion for acute kidney injury in critically ill patients. <italic toggle="yes">Nephrol. Dialysis Transplantation</italic>. <bold>26</bold>, 509&#8211;515 (2011).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfq332</pub-id><pub-id pub-id-type="pmcid">PMC3108356</pub-id><pub-id pub-id-type="pmid">20562094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Linda, L. &amp; Ng <italic toggle="yes">Center for Drug Evaluation and Research (CDER) Reviewer Guidance-Validation of Chromatographic Methods</italic> (1994).</mixed-citation></ref></ref-list></back></article></pmc-articleset>